Editas Medicine Inc
EDIT2.545USD
+0.105+4.30%
交易中 （美東）報價延遲15分鐘
213.04M總市值
虧損本益比TTM
關於 Editas Medicine Inc 公司
Editas Medicine, Inc. 是一家臨牀階段的基因組編輯公司。該公司專注於開發具有潛在變革性的基因組藥物，以治療多種嚴重疾病。該公司已開發出基於 CRISPR 技術的專有基因編輯平臺。CRISPR 使用由酶組成的蛋白質-核糖核酸 (RNA) 複合物，包括 CRISPR 相關蛋白 9 (Cas9) 或 Cas12a（來自 Prevotella 和 Francisella 1 的 CRISPR，也稱爲 Cpf1），與旨在識別特定脫氧核糖核酸 (DNA) 序列的引導核糖核酸 (RNA) 分子結合。該公司致力於體內給藥基因編輯藥物的開發，其中將藥物注射或輸注到患者體內以編輯其體內的細胞。其主要項目 reni-cel 是一種實驗性的體外基因編輯藥物，用於治療鐮狀細胞病 (SCD)，這是一種導致過早死亡的嚴重遺傳性血液病，以及輸血依賴性β地中海貧血 (TDT)。
公司簡介
公司代碼EDIT
公司名稱Editas Medicine Inc
上市日期Feb 03, 2016
CEODr. Gilmore O'Neill
員工數量246
證券類型Ordinary Share
年結日Feb 03
公司地址11 Hurley St
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02141-2110
電話16174019000
網址https://www.editasmedicine.com/
公司代碼EDIT
上市日期Feb 03, 2016
CEODr. Gilmore O'Neill
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
Mr. Andrew J. Hirsch
Mr. Andrew J. Hirsch
Independent Director
Independent Director
--
--
Dr. Elliott M. Levy, M.D.
Dr. Elliott M. Levy, M.D.
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. Jessica Hopfield, Ph.D.
Dr. Jessica Hopfield, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
67.70K
--
Ms. Amy Parison
Ms. Amy Parison
Chief Financial Officer, Senior Vice President, Treasurer
Chief Financial Officer, Senior Vice President, Treasurer
17.51K
-2.48%
Dr. Gilmore O'Neill
Dr. Gilmore O'Neill
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. David T. Scadden, M.D.
Dr. David T. Scadden, M.D.
Independent Director
Independent Director
--
--
Dr. Linda C. Burkly, Ph.D.
Dr. Linda C. Burkly, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
--
--
Ms. Bernadette M. Connaughton
Ms. Bernadette M. Connaughton
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 6月7日 週六
更新時間: 6月7日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
8.92%
BlackRock Institutional Trust Company, N.A.
7.26%
Morgan Stanley & Co. LLC
3.05%
Two Sigma Investments, LP
2.94%
Geode Capital Management, L.L.C.
2.32%
Other
75.50%
股東類型
持股股東
佔比
Investment Advisor
30.95%
Investment Advisor/Hedge Fund
12.97%
Research Firm
6.63%
Hedge Fund
5.44%
Bank and Trust
0.80%
Venture Capital
0.57%
Individual Investor
0.33%
Family Office
0.21%
Pension Fund
0.04%
Other
42.06%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
526
48.45M
57.87%
-23.30M
2025Q1
560
48.21M
57.60%
-23.68M
2024Q4
576
55.95M
67.78%
-11.28M
2024Q3
585
59.63M
72.30%
-8.64M
2024Q2
584
60.69M
73.86%
-19.13M
2024Q1
583
72.72M
88.97%
+367.05K
2023Q4
602
63.06M
77.30%
-13.98M
2023Q3
641
65.84M
80.91%
-11.78M
2023Q2
659
66.65M
82.05%
-208.12K
2023Q1
669
56.55M
82.00%
-9.39M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
7.47M
8.92%
+643.26K
+9.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.08M
7.26%
-551.77K
-8.32%
Mar 31, 2025
Morgan Stanley & Co. LLC
2.55M
3.05%
+1.36M
+113.76%
Mar 31, 2025
Two Sigma Investments, LP
2.46M
2.94%
-841.30K
-25.45%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.94M
2.32%
+135.21K
+7.48%
Mar 31, 2025
State Street Global Advisors (US)
1.85M
2.21%
-26.11K
-1.39%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.61M
1.92%
-551.03K
-25.52%
Mar 31, 2025
UBS Asset Management (Switzerland)
1.60M
1.91%
+430.00K
+36.75%
Mar 31, 2025
BofA Global Research (US)
1.52M
1.81%
+1.08M
+250.36%
Mar 31, 2025
UBS Asset Management Switzerland AG
1.17M
1.4%
+1.17M
--
Jan 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
WisdomTree BioRevolution Fund
1.56%
Invesco NASDAQ Future Gen 200 ETF
0.58%
AXS Green Alpha ETF
0.29%
iShares Micro-Cap ETF
0.03%
Invesco Nasdaq Biotechnology ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares Ultra Nasdaq Biotechnology
0.02%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
查看更多
WisdomTree BioRevolution Fund
佔比1.56%
Invesco NASDAQ Future Gen 200 ETF
佔比0.58%
AXS Green Alpha ETF
佔比0.29%
iShares Micro-Cap ETF
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.02%
iShares Biotechnology ETF
佔比0.02%
ProShares Ultra Nasdaq Biotechnology
佔比0.02%
iShares Russell 2000 ETF
佔比0.01%
Proshares Ultra Russell 2000
佔比0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
